Access to future treatments
Clinical trials don’t just advance science; they also serve as in-the-moment treatment alternatives for patients.
iClusion aims to make the clinical trial process faster, more effective, and more accessible for cancer patients and oncologists. The Trial Eye platform connects study sponsors, study sites, oncologists and their patients in a closed-loop ecosystem.
Rather than each group remaining siloed Trial Eye invites various stakeholders to connect and start up clinical trials and recruit patients in a fast & easy, transparent & accessible and harmonized & standardized manner. This speeds up clinical trial processes and patient recruitment and therefore the entire drug development process.
iClusion believes its network model is nothing short of revolutionary. This is the only initiative designed from the viewpoint of the 2 most important stakeholders within clinical trials; the patient and their treating physician. If they have easy access to clinical trials and can participate, drug development can speed up.
The footprint iClusion wants to leave on this planet, through professional service Trial Eye and public service Heyleys is changing the lives of patients.
The Trial Eye Paradigm
A revolutionary online infrastructure resulting in
By harmonizing and standardizing processes for both study sponsor and study site.
By decreasing administrative workload, study sites can perform more trials for more patients.
Automated workflows facilitate fast local approval and initiation of clinical trials speeding up drug development.
All network sites updated with one click on new trials and new or amended trial documents.
Frequently Asked Questions
CRO’s often offer many more clinical trial services (like protocol writing and national approvals) but their main and most important task remains data capture, monitoring and analysis. Once a trial is locally approved initiation will take place by the sponsor or CRO.
Once a patient is matched and informed, the patient is randomized and included by the sponsor or CRO within their systems and data capture, monitoring and analyzing is thus not done within the Trial Eye infrastructure.
Its patients’ profiles that will be linked to possible suitable trials. By studying the actual protocol the physician can then decide if the patient actually can be included and start the ICF procedure. The signed document will only be stored physically within the study site and/or digitally within the sponsor’s or CRO’s system. The Trial Eye infrastructure only provides a standardized procedure to access, start and monitor ICF procedures.
Each event of matching a patient will generate a unique Trial Eye event number that can be tracked on informing and routing towards the sponsor or CRO systems for randomization and/or inclusion.